Resident
Shi, Ruolin (Lilian), Pharm.D.
Residency Program
LMPS
Project Title
SGLT2 Inhibitor Eligibility for Patients Hospitalized with Acute Heart Failure (SGLT2i AHF)
Investigators
Chua, Doson, B.Sc.(Pharm.), Pharm.D., FCSHP, BCPS, BCCP; Turgeon, Ricky, B.Sc.(Pharm.), ACPR, Pharm.D.
Abstract
SLGT2 inhibitors have demonstrated consistent clinical benefits in chronic heart failure with reduced ejection fraction (HFrEF), leading to their inclusion as a part of guideline-directed medical therapy. Furthermore, emerging evidence supports the safety and efficacy of early initiation of SGLT2 inhibitors in acute HF. Despite these findings, clinicians are often hesitant to initiate SGLT2 inhibitors during an acute hospitalization. We conducted a retrospective chart review to evaluate the real-world generalizability of published and ongoing SGLT2 inhibitor randomized controlled trials (RCTs) to patients hospitalized for HFrEF.
